logo
Twitter
Discord
Email
logo
Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

NASDAQ•LXRX
CEO: Mr. Brian T. Crum
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2000-04-07
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Contact Information
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, 77381, United States
281-863-3000
www.lexpharma.com
Market Cap
$617.78M
P/E (TTM)
-9.0
37
Dividend Yield
--
52W High
$1.83
52W Low
$0.28
52W Range
92%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$14.18M+710.40%
4-Quarter Trend

EPS

-$0.04-77.78%
4-Quarter Trend

FCF

$0.00-100.00%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Licensing Revenue Spike Licensing revenue reached $40.7M for nine months ended September 30, 2025, primarily from Novo Nordisk agreement recognition.
Net Loss Significantly Reduced Nine months net loss narrowed to $(34.8M) versus $(166.6M) reported in the prior year period.
Strong Liquidity Position Total cash and short-term investments stood at $144.950M as of September 30, 2025, supporting operations.
Operating Expense Control Nine months SG&A expenses dropped 74% to $28.6M following late 2024 restructuring actions.

Risk Factors

R&D Success Dependency Business heavily relies on successful drug program completion; failure risks significant stock price decline.
Regulatory Approval Uncertainty Drug candidates face lengthy, uncertain regulatory processes potentially limiting or preventing commercialization approvals.
Substantial Indebtedness Limits Existing substantial indebtedness may limit available cash flow needed for ongoing business investment requirements.
Future Capital Needs Additional capital required for Phase 3 development; unavailability forces program delays or scope reduction.

Outlook

Pipeline Advancement Focus Expect continued substantial capital devotion to research and development for advancing current drug candidates.
Sufficient 12-Month Runway Current unrestricted cash and expected collaboration revenues fund planned operations for at least 12 months.
Debt Covenant Compliance Company confirmed full compliance with all financial covenants under the Oxford Term Loans as of September 30, 2025.
Stock Sales Flexibility $75M Open Market Sale Agreement capacity remains fully available for potential future equity financing needs.

Peer Comparison

Revenue (TTM)

REGENXBIO Inc.RGNX
$161.32M
+91.3%
Lexicon Pharmaceuticals, Inc.LXRX
$70.86M
+1255.2%
Gossamer Bio, Inc.GOSS
$44.05M
-60.7%

Gross Margin (Latest Quarter)

Ocugen, Inc.OCGN
100.0%
+0.0pp
Bicycle Therapeutics plcBCYC
100.0%
+1705.8pp
Gossamer Bio, Inc.GOSS
100.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CRVS$1.87B-137.9-25.8%1.3%
RGNX$698.09M-4.0-78.3%51.1%
GOSS$624.93M-3.9593.8%97.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-18.9%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 5, 2026
|
EPS:-$0.07
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $14.18M+710.4%
    |
    EPS: $-0.04-77.8%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $28.87M+1652.6%
    |
    EPS: $0.01-105.3%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|
    Revenue: $1.26M+11.7%
    |
    EPS: $-0.07-65.0%
    Meet

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 7, 2025|
    Revenue: $31.08M+2481.5%
    |
    EPS: $-0.63+21.3%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 13, 2024|
    Revenue: $1.75M+980.2%
    |
    EPS: $-0.18-14.3%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 2, 2024|
    Revenue: $1.65M+419.6%
    |
    EPS: $-0.17-22.7%
    Meet

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $1.13M+4608.3%
    |
    EPS: $-0.20+25.0%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 25, 2024|
    Revenue: $1.20M+766.2%
    |
    EPS: $-0.80-29.0%
    Miss